Marc Mazur
Known title: DirectorCIK: 0001361226
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Transaction History
| NSLR | ▲ Buy | Grant | 3,536 | $0 | 6/10/2026 | View on chart |
| NSLR | ▲ Buy | Grant | 7,812 | $0 | 5/28/2025 | View on chart |
| NSLR | ▲ Buy | Grant | 12,048 | $0 | 6/5/2024 | View on chart |
| CELU | ▲ Buy | Grant | 199,921 | $0 | 6/14/2023 | View on chart |
| NSLR | ▲ Buy | Grant | 15,015 | $0 | 5/31/2023 | View on chart |
| CELU | ▲ Buy | Grant | 36,145 | $0 | 7/13/2022 | View on chart |
| NSLR | ▲ Buy | Grant | 6,684 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Neostellar Capital faces skepticism on growth potential
A recent SeekingAlpha article questions whether Neostellar Capital can achieve its ambitious goals, suggesting not all companies in the sector will succeed. This narrative adds context to the stock's current valuation, which sits near its 52-week low. The company maintains a low P/E ratio and a notable dividend yield, but investor sentiment remains cautious.
Neostellar Capital faces skepticism on growth potential. A recent SeekingAlpha article questions whether Neostellar Capital can achieve its ambitious goals, suggesting not all companies in the sector will succeed. This narrative adds context to the stock's current valuation, which sits near its 52-week low. The company maintains a low P/E ratio and a notable dividend yield, but investor sentiment remains cautious.